This is a preview. Log in through your library . Abstract It is difficult to distinguish pulmonary disease due to Mycobacterium avium complex (MAC) from that due to other mycobacteria, such as ...
Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...
The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium ...
In a large, diverse cohort of human immunodeficiency virus (HIV)-infected persons receiving routine care, the proportion of eligible persons who discontinued primary prophylaxis against Mycobacterium ...
Dear Dr. Roach: My husband is being tested to confirm the pulmonologist’s tentative diagnosis of mycobacterium avium complex. He was a relatively healthy person up to this point, so could you please ...
The FDA established the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as part of the 21st Century Cures Act that was signed into law in December 2016. The LPAD ...
Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback